|
|
Article: Cordis Begins Dual Antiplatelet Therapy Trial.
- Article from:
- Health & Beauty Close-Up
- Article date:
- September 3, 2009
CopyrightCOPYRIGHT 2009 Close-Up Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cordis Corp., a company engaged in the development and manufacture of interventional vascular technology, announced that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent.
In a release, the Company noted:
The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
CYPRESS will provide data to support the clinical evaluation of the company's new NEVO Sirolimus-eluting Coronary Stent in the NEVO III trial, a ...